Judge Says Fund's Off-Label Promotion Claims Don't Implicate FDCA
October 15, 2007
DOCUMENTS
- Opinion
PHILADELPHIA - State law claims arising from off-label promotion of three atypical antipsychotic drugs do not conflict with federal laws governing prescription drug labeling such that a state benefit fund's lawsuit accusing the drugs' manufacturers of fraud and failure to warn belong in federal court, a judge has ruled. Pennsylvania Employees Benefit Trust Fund v. Eli Lilly & Company Inc., et al., No. 07-2057 (E.D. Pa.).
In an Oct. 5 decision, Judge Gene E.K. Pratter of the U.S. District Court for the Eastern District of Pennsylvania instead ruled that state law allegations that the drug companies illegally marketed their drugs …
UPCOMING CONFERENCES
![](https://harrismartin.s3.amazonaws.com/media/CACHE/images/uploads/conferences/iStock-115753557_fLooJhx/ebadaa70c9ae4eba2f27c08bcd68c09c.jpg)
HarrisMartin's Midwest Asbestos Litigation Conference
September 27, 2024 - St. Louis, MO
Four Seasons Hotel, St. Louis